Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Michigan for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Michigan only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Michigan (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jeffrey Margolis (NPI 1871577544)

Field	Value
Entity Type	Individual
Organization	Jeffrey Margolis
Address	27301 Dequindre Rd
City	Madison Heights
State	MI
ZIP	48071
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 6, 2005

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

JEFFREY MARGOLIS is a Hematology & Oncology Physician with lifetime Medicare revenue of $3M and no Medicaid billing on file, and his NPI was enumerated on 2005-12-06 (~21 years ago). This combination of long tenure and a Medicare-only billing footprint indicates an established, predominantly Medicare-facing oncology practice rather than a mixed Medicaid/Medicare clinic network.

Revenue is highly concentrated in a small set of injectable oncology agents: the top 3 Medicare codes account for 64.8% of this provider's total Medicare revenue. Specifically, J9271 shows 29.6K claims, $43 avg paid/claim, $1.3M revenue (43.2% of this provider's total Medicare revenue); J0897 shows 18.1K claims, $18 avg paid/claim, $326.2K revenue (11.1% of this provider's total Medicare revenue); and J2353 shows 1.9K claims, $161 avg paid/claim, $310.7K revenue (10.5% of this provider's total Medicare revenue), together driving the majority of billings.

The overall code mix—heavy on J9271 (pembrolizumab), J0897 (denosumab), J2353 (octreotide depot), and multiple chemotherapy administration codes—signals an infusion-centric oncology practice that delivers systemic biologics and supportive-care injectables alongside episodic E/M visits. Complementary utilization of infusion/chemotherapy administration codes such as 96413 (876 claims, $91.1K revenue) and 96367 (1.2K claims, $27.3K revenue) plus lab codes 80047 (2.9K claims, $37.3K revenue) and 85025 (3.2K claims, $25.4K revenue) reinforces an on-site infusion and monitoring workflow.

Against national peers this provider ranks as a notably high-volume biller for several key drugs: J9271 ranks #126 of 1841 providers nationally (93th percentile; notably above typical national volume for this code) and J0897 ranks #354 of 10057 providers nationally (96th percentile; notably above typical national volume for this code), indicating strong competitive standing in administering these biologics. J2353 ranks #3 of 18 providers nationally (88th percentile; typical, unremarkable volume for this code), so for octreotide depot the provider appears prominent among the small subset that bills it.

Several non-drug codes are statistical outliers, consistent with high outpatient throughput: 99214 (1.4K claims, $144.9K revenue) ranks #4003 of 479517 providers nationally (99th percentile; extreme outlier) and 99213 (1.6K claims, $113.8K revenue) ranks #1695 of 457151 providers nationally (100th percentile; extreme outlier). Chemotherapy administration 96413 is also an extreme outlier (rank #127 of 7514, 98th percentile), and basic lab panel 80047 ranks in the 99th percentile, all of which point to sustained, high-volume clinical activity per Medicare billing records.

The payer mix is effectively single-payer from an operational perspective: Medicare accounts for the reported $3M lifetime revenue while Medicaid shows no billing on file. Analysts should treat this practice as Medicare-dependent when modeling reimbursement sensitivity, utilization trends, and contract negotiations, and should not assume Medicaid encounter experience or state-level Medicaid relationships.

Clinical and contracting implications follow from the concentration in biologics and biosimilars: high-volume billing for injectable agents (including biosimilar codes such as Q5106, Q5119 and pegfilgrastim entries Q5108/J2506) suggests focus areas for drug acquisition cost, inventory management, and prior authorization patterns. For payers and provider-relations teams, negotiation levers and utilization management strategies should prioritize oncology drug pathways, infusion capacity, and supportive-care protocols (e.g., growth factor and immune globulin use) given their outsized contribution to revenue.

Taken together, the provider presents as an established, infusion-oriented oncology practice with concentrated revenue exposure to a few high-volume injectable agents, strong national ranking on key biologics, and extremely high E/M and infusion administration activity in Medicare claims. These patterns indicate both predictable clinical pathways (systemic oncology care) and targeted commercial opportunities for payers around drug cost controls, prior authorization efficiency, and capacity planning.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,600	$40	$1.3M
J0897	Injection, denosumab, 1 mg	18,120	$20	$326.2K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	1,930	$160	$310.7K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,660	$40	$239.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,450	$100	$144.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,630	$70	$113.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	880	$100	$91.1K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	12,000	$10	$72K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,060	$20	$70.4K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	470	$90	$42.6K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Michigan Distribution

Jeffrey Margolis — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Michigan

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	8,800	$40	$473.6K
J2353	1	10	1,930	$160	$310.5K
J1569	4	10	4,550	$40	$197.2K
J0897	3	170	2,460	$20	$69.1K
Q5119	1	10	2,300	$20	$50.8K
Q5108	4	10	310	$100	$39.1K
J2506	6	10	340	$80	$27.8K
J9305	1	10	2,100	$10	$26.6K
J9217	30	80	140	$130	$22.5K
Q5106	1	20	1,300	$10	$18.8K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jeffrey Margolis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
William Beaumont Hospital	MI	Hospitalist Physician	$0	$167.9M
Oakwood Healthcare, Inc.	MI	General Acute Care Hospital	$0	$165.3M
William Beaumont Hospital	MI	General Acute Care Hospital	$0	$162.4M
Michigan Healthcare Professionals PC	MI	Internal Medicine Physician	$0	$106.2M
William Beaumont Hospital	MI	General Acute Care Hospital	$0	$84.8M
Oakwood Ambulatory LLC	MI	Internal Medicine Physician	$0	$66.9M
William Beaumont Hospital	MI	General Acute Care Hospital	$0	$61.5M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wellstreet Urgent Care Of Michigan	MI	Urgent Care Clinic/Center	$0	$37.5M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M

Nearby Providers

Other providers in the same ZIP code as Jeffrey Margolis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Northwood Inc	MI	Durable Medical Equipment & Medical Supplies	$0	$39.5M
Henry Ford Health Macomb Oakland Hospital	MI	General Acute Care Hospital	$0	$24.8M
Sacred Heart Rehabilitation Center, Inc	MI	Community/Behavioral Health Agency	$206.2K	$11.1M
William Beaumont Hospital	MI	Home Health Agency	$0	$5.3M
Clinical Connect Laboratories, LLC	MI	Clinical Medical Laboratory	$1.4M	$3.8M
Db Labs LLC	MI	Clinical Medical Laboratory	$144.9K	$3.1M
Savitha Balaraman	MI	Medical Oncology Physician	$1.1M	$0
Gary Langnas	MI	Internal Medicine Physician	$493.6K	$0
James Kohlenberg	MI	Internal Medicine Physician	$323.5K	$0
Ryan Chartrand	MI	Urology Physician	$233.7K	$0

Jeffrey Margolis — Billing Profile & Reimbursement Data

Sign up for Jeffrey Margolis — Billing Profile & Reimbursement Data policy alerts

Jeffrey Margolis — Billing Profile & Reimbursement Data

Sign up for Jeffrey Margolis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References